1. Home
  2. A2M (Access to health technologies)

A2M (Access to health technologies)

A2M (Access to health technologies)

Cataclysmic: The Proposed Dismantling of the Médecins Sans Frontières Access Campaign Strikes At the Heart of Influential Activism, Political-Legal Battles in Global Health At Stake
Transparency and access to medical products
Report highlights gaps in access, stewardship plans for promising antimicrobials
Examples of US competition cases that mandate transfer of technology and know-how
Moderna’s Outsized Price Ask for COVID Vaccines in South Africa Highlights Need to ‘Rein in Corporates’ in Pandemics
Documents reveal how Pfizer and Moderna ‘profiteered’ in Covid-19 vaccine negotiations
Moderna Cancels Kenya Vaccine Project Due to Familiar Economic Hurdles
The WTO Failed the World in Covid Pandemic-related technology and intellectual property cannot remain in its authority.
WHO IHR Negotiators Agree on Special Session on Equity
Evergreening of Medicine Patents is ‘Abuse’ of Intellectual Property System
Fair Medicines Pricing requires addressing monopolies and increasing transparency in pharmaceutical markets
Reigniting the Spirit of the Doha Declaration: Why a TRIPS Waiver Extension is Key to the Legitimacy of the World Trade Organization
Biden’s got pharma’s back in global pandemic treaty negotiations
Lower Drug Costs Are Just a Federal License Away. But They Require Biden Administration Leadership
Serum Institute of India joins CEPI global network to boost production of affordable outbreak vaccines
New initiative supports equitable regional vaccine manufacturing
TRIPS Waiver Decision for Equitable Access to Medical Countermeasures in the Pandemic: COVID-19 Diagnostics and Therapeutics
USITC report confirms inadequacy of VLs, tier-pricing, access schemes
Johnson & Johnson’s Patenting & Pricing Strategy for TB Medicine Bedaquiline: A Cautionary Tale for New TB Medicines
Global inequities in access to COVID-19 health products and technologies: A political economy analysis
EU trade deals risk affordability of generic medicines for Global South
Some Cancer Drugs Excluded from New WHO Essential Medicines List Because of Cost
Discussion Paper on IP and Access to Publicly Funded Research Results in Health Emergencies. Publicly Funded International R&D Projects
Opinion: Fighting epidemics takes equitable medical countermeasures
Ebola Inequity Reinforces Need for Comprehensive Access & Benefit Sharing Mechanism
Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support
Ensuring Access to New Treatments for Ebola Virus Disease
Intellectual Property, Innovation and Public Health at WHO: a Chronology
For the first time, WHO committee recommends action on high-priced essential medicines
Subscribe to A2M (Access to health technologies)